Malladi Drugs & Pharmaceuticals IPO (DRHP filed)
Malladi Drugs & Pharmaceuticals Limited filed its draft red herring prospectus with SEBI on 1 Oct 2026. Price band, lot size and issue dates are announced only after SEBI observations and the RHP filing.
Last updated
- Stage
- DRHP Filed
- DRHP filed
- 1 Oct 2026
- Days since
- 30
- Issue size
- —
- Board
- Mainboard
- Price band
- TBA
Malladi Drugs & Pharmaceuticals IPO status
Malladi Drugs & Pharmaceuticals Limited filed its draft red herring prospectus (DRHP) with SEBI on . The issue can open only after SEBI issues its observations and the company files the RHP with the price band.
| DRHP filed | 1 Oct 2026 |
|---|---|
| Days since filing | 30 |
| SEBI observation | Awaited |
| Price band | TBA |
| Issue dates | TBA |
Objectives
The company intends to allocate the net proceeds from the offering to the following objectives.
| Sr | Objective |
|---|---|
| 1 | The Malladi Drugs & Pharmaceuticals Ltd. IPO is a 100% Offer for Sale (OFS), so the company will not receive any funding and the entire IPO proceeds will go to the selling shareholders. |
About Malladi Drugs & Pharmaceuticals Limited
Established in 1980, Malladi Drugs & Pharmaceuticals Limited is a pharmaceutical company specializing in the research, development and manufacture of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. Initially focused on the production of Ephedrine and Pseudoephedrine salts, the company has progressively expanded its capabilities through research and innovation, product development, regulatory expertise and advanced manufacturing infrastructure.
The company operates three manufacturing facilities across Tamil Nadu and Andhra Pradesh, supplying pharmaceutical products to markets in more than 150 countries. With exports accounting for approximately 85% of its revenue, Malladi Drugs & Pharmaceuticals has established a strong presence in international markets. Its workforce of over 1,500 professionals supports its manufacturing, research and development, quality assurance and regulatory functions.
Malladi Drugs & Pharmaceuticals has filed and secured approvals for 22 Drug Master Files (DMFs) with regulatory authorities, including the USFDA, KFDA, CDSCO, PMDA, ANVISA and Health Canada. In addition, the company holds six Certificates of Suitability (CEPs) for key products, demonstrating its commitment to quality standards and supporting its presence in highly regulated global pharmaceutical markets.
Contact details
Malladi Drugs & Pharmaceuticals Ltd.
SKCL Tech Square,
7th Floor, Plot No. SP 14,
Thiru Vi Ka Industrial Estate, Guindy
Chennai, Tamil Nadu, 600032
Telephone: 44 6687 6900
Email: info@malladi.co.in
Website: https://www.malladi.com/
Malladi Drugs & Pharmaceuticals IPO FAQs
- Has Malladi Drugs & Pharmaceuticals IPO filed for an IPO?
- Malladi Drugs & Pharmaceuticals Limited filed its draft red herring prospectus (DRHP) with SEBI on 1 Oct 2026.
- When will the Malladi Drugs & Pharmaceuticals IPO open?
- Issue dates are announced after SEBI observations and the RHP filing. They are not available yet.
- What is the Malladi Drugs & Pharmaceuticals IPO price band?
- The price band is announced a few days before the issue opens. It is not available yet.
Details are from the draft prospectus and can change in the final RHP. This is not investment advice.